Study of Radiation with Chemoimmunotherapy for Borderline Resectable NSCLC
This study is looking at whether adding radiation (SBRT) before standard chemotherapy and immunotherapy (nivolumab) is helpful for people with non-small cell lung cancer (NSCLC) that doctors consider "borderline resectable" (meaning surgery might be possible). You would receive nivolumab intravenously every 3 weeks for up to 9 weeks, along with standard chemotherapy options like carboplatin or cisplatin plus pemetrexed, paclitaxel, or gemcitabine. The SBRT radiation would be given over three days, within 7 days of starting chemoimmunotherapy. After this treatment, doctors will evaluate if surgery is possible. The main goal is to see how well people tolerate this combination treatment. This study is open to adults aged 18 and older with specific types of NSCLC, and is currently recruiting 18 participants.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 18 participants.
- What's involved
- You would receive nivolumab intravenously every 3 weeks for up to 9 weeks, along with chemotherapy. You would also receive SBRT radiation over three days, within 7 days of starting chemoimmunotherapy. After treatment, you will be evaluated for surgical resection.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your tolerability to the treatment will be measured at 20 weeks after starting the initial therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
4 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Tolerability of Adding Sub-ablative, Immunosensitizing, Radiotherapy to Standard of Care Neoadjuvant Chemoimmunotherapy20 weeks post initiation of neoadjuvant therapy
Evaluate the tolerability of adding sub-ablative, immunosensitizing, radiotherapy to standard of care neoadjuvant chemoimmunotherapy prior to surgery for resectable NSCLC, measured by the rate of DLTs from time of neoadjuvant therapy initiation to start of definitive therapy (either surgery or chemoimmunotherapy initiation).